ATORVASTATIN MYLAN 40 MG TBL FLM 100

What is the maximum co-payment for ATORVASTATIN MYLAN?

If the insurance company contributes, the maximum co-payment is 0,00 Kč. The maximum pharmacy price is 252,21 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does ATORVASTATIN MYLAN have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

287,90 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

The medicine has no indication restriction. Its reimbursement is not conditional on a specific diagnosis or clinical condition.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe ATORVASTATIN MYLAN?

Prescription is not conditional on a medical specialization.

What is the composition of ATORVASTATIN MYLAN?

Trihydrát vápenaté soli atorvastatinu (43,376 mg), atorvastatin (40 mg), koloidní bezvodý oxid křemičitý, uhličitan sodný, neznámá látka s kódem 3755, arginin, laktosa, sodná sůl kroskarmelosy, neznámá látka s kódem 4336, magnesium-stearát, neznámá látka s kódem 17846, oxid titaničitý, neznámá látka s kódem 4077, ointmentek. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Documents could not be found

Which medicines are similar to ATORVASTATIN MYLAN?

The medicine belongs to ATC group C10AA05 – ATORVASTATIN. Medicines with the same active substance can be found here.

Who manufactures ATORVASTATIN MYLAN?

VIATRIS LIMITED, Dublin (IRL)

Is the medicine in shortage?

The latest report from the manufacturer is from 18. 3. 2024. Production was terminated with effect from 26. 3. 2024. The manufacturer lists medicines with the following code as a potential substitute: